A global rise in cancer prevalence has led to advancements in diagnostic techniques. As per GLOBOCAN 2020, the prevalence of cancer is estimated at 19,292,789 cases worldwide, out of which the estimated prevalence of breast cancer is 2,261,419 cases. The rising geriatric population and the increasing prevalence of cancer have increased the burden on healthcare systems in major countries such as the U.S., Japan, and China. Tissue diagnostics is an important diagnostic technique for diseases such as cancer. The rising focus on personalized medicines is gradually increasing the use of tissue diagnostics for understanding the prognosis of diseases.
In its latest publication on tissue diagnostics, Meticulous Research® states that the global Tissue Diagnostics Market is projected to reach $8.52 Billion by 2029, at a CAGR of 7.4% from 2022 to 2029.
The global tissue diagnostics market is segmented by Product Type (Consumables [Antibodies, Kits, Reagents], Instruments [Slide Staining Systems, Slide Scanners, Tissue Processing Systems, Other Instruments {Microarray, Embedding System]), Technology (Immunohistochemistry, In-situ Hybridization, Digital Pathology, H&E Slide Staining, Other Technologies, Application (Breast Cancer, Lung Cancer, Colorectal and Gastrointestinal Cancer, Prostate Cancer, Lymphatic Cancer, Other Applications), End User (Hospitals and Reference Laboratories, Research Institutes, Pharmaceutical Companies, and Contract Research Organization). The study also evaluates industry competitors and analyzes their market shares at the global and regional levels.
Based on geography, in 2022, North America is expected to account for the largest share of this market. The growth of this regional market is attributed to the high incidences of cancer, the presence of several cancer awareness and diagnosis programs, and the availability of advanced cancer diagnosis and treatment options.
Based on product type, in 2022, the consumables segment is expected to account for the largest share of the market. Consumables are widely consumed throughout tissue diagnostics, from initial preservation to tissue staining and post-tissue preservation. They are extensively and recurrently. These benefits contribute to the large market share of this segment.
Based on technology, the tissue diagnostics market is segmented into immunohistochemistry (IHC), in-situ hybridization, digital pathology, H&E staining, and other technologies. In 2022, the IHC segment is expected to account for the largest share of the market. IHC provides variations between different types of tumors, unlike conventional techniques wherein only a restricted number of tissue structures are detected. Additionally, the upsurge in point-of-care diagnostics and the growth in in-vitro diagnostics are the factors contributing to the large market share of this segment.
Request Sample Report: https://www.meticulousresearch.com/request-sample-report/cp_id=4971
Based on application, in 2022, the breast cancer segment is expected to account for the largest share of the global tissue diagnostics market. The large market share of this segment is attributed to the high prevalence of breast cancer globally and the increased investments supporting breast cancer research and screening programs.
Based on end user, the tissue diagnostics market is segmented into hospital and reference laboratories, research institutes, pharmaceutical companies, and contract research organizations. In 2022, the hospitals and reference laboratories segment is expected to account for the largest share of the market. The growth of this segment is attributed to the high adoption of advanced tissue-based diagnostic techniques in hospitals and reference laboratories.
Key Players
The report provides competitive intelligence in terms of financials, growth strategies, product portfolios, and geographical presence of some of the key players operating in the global tissue diagnostics market, such as F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Sigma-Aldrich Co. LLC) (Germany), Sakura Finetek Japan Co., Ltd. (Japan), Abcam plc (U.K.), Becton, Dickinson, and Company (U.S.), QIAGEN N.V. (Netherlands), Cell Signaling Technology, Inc. (U.S.), Bio-Genex Laboratories, Inc. (U.S.), Bio SB, INC (U.S.), 3DHISTECH Ltd. (Hungary), and HOLOGIC, INC. (U.S.).
Download Free Sample Report :https://www.meticulousresearch.com/download-sample-report/cp_id=4971
Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
